CStone's NDA for Ayvakit in Molecularly Defined Stomach Cancer Accepted by Chinese Regulators

Apr 23, 2020

|

NEW YORK – CStone Pharmaceuticals said on Thursday that its new drug application of avapritinib (Ayvakit) for PDGFRA exon 18-mutated metastatic or unresectable gastrointestinal stromal tumors was accepted by China's National Medical Products Administration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

CStone's NDA for Ayvakit in Molecularly Defined Stomach Cancer Accepted by Chinese Regulators

To read the full story....

Breaking News

Genetic Testing Challenges in Oncology: Missed Mutations Highlight Somatic, Germline Test Difference

Takeda's Alunbrig Gets First-Line FDA Approval With Abbott CDx in ALK-Positive Lung Cancer

Invivoscribe Receives Supplemental Approval for AML Kit

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Genentech's Tecentriq Receives First-Line FDA Approval for High PD-L1-Expressing Lung Cancer

What's Popular?

Takeda's Alunbrig Gets First-Line FDA Approval With Abbott CDx in ALK-Positive Lung Cancer

Opdivo, Yervoy Another First-Line Option in NSCLC, Though Maybe Not Some Oncologists' Top Choice

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Invivoscribe Receives Supplemental Approval for AML Kit

Sponsorships